T-LGLL
Conditions
Interventions
test group:Bortezomib combined with arsenic trioxide chemotherapy
Sponsors
The Second Affiliated Hospital of Dalian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1: T-LGLL was clearly diagnosed according to WHO criteria 2: The disease state is primary or the treatment of immunosuppression is ineffective 3: There is at least one-line cytopenia: the absolute value of neutrophils is less than 0.5× 10 9/L, there are anemia symptoms, hemoglobin is less than 90g/L, and platelet count is less than 50× 10 9/L. 4: Aged 18 to 80 years 5: ECOG physical condition score was <= 2 6: No serious complications, such as liver failure, renal failure, heart failure 7: Must be able to understand the protocol, follow medical instructions and sign informed consent.
Exclusion criteria
Exclusion criteria: 1: Who is receiving either a chemotherapy regimen or a targeted drug 2: Major surgery (excluding diagnostic surgery) performed within the past 4 weeks 3: Evidence of central nervous system disease 4: Active infectious diseases, such as HBV, HCV, tuberculosis 5: Serious diseases that may limit patients' participation in the trial (such as progressive infection, uncontrolled diabetes, severe cardiac insufficiency or myocardial infarction, liver and kidney dysfunction, etc) 6: Participating in other clinical trials or participating in clinical trials of other drugs within 3 months 7: Women of childbearing age must have a negative pregnancy test and agree to use effective contraception during treatment and within a year thereafter 8: There are allergies or contraindications to any of the drugs involved in the protocol 9: Unable to understand the experimental protocol, follow the doctor's advice, or refuse to sign the informed consent 10: The researchers say it is not appropriate for patients who are treated with this regimen.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete remission rate after 2 times of chemotherapy; | — |
Secondary
| Measure | Time frame |
|---|---|
| adverse event incidence rate; | — |
Countries
China
Contacts
Public ContactJinsong Yan
Second Hospital of Dalian Medical University
Outcome results
None listed